ArticleMedicine2026
Bidirectional Mendelian randomization analysis of the relationships between blood cell phenotypes, genetic variants, and systemic lupus erythematosus.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Based on a bidirectional two-sample Mendelian randomization (MR) analysis of 91 blood cell phenotypes and systemic lupus erythematosus (SLE), this study provides genetic evidence for a complex causal interplay between specific immune cell functions and SLE susceptibility. Forward MR analysis identified 4 perturbation responses - involving eosinophils (response to colchicine), neutrophils (response to potassium chloride and lipopolysaccharide), and platelets (response to nigericin) - as causally linked to SLE risk, with 3 increasing and 1 decreasing susceptibility. Reverse MR analysis revealed that genetic liability to SLE influences 5 blood cell perturbation responses, primarily attenuating neutrophil, monocyte, and white blood cell reactivity. These findings suggest that dysregulated functional responses in key immune cells may act as upstream drivers in SLE pathogenesis, while SLE genetic risk also feeds back to alter cellular behavior, highlighting potential biomarkers and therapeutic targets for SLE prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.